BACKGROUND AND OBJECTIVE: In this era of increasing options for treatment of 'surgical' lung cancer patients, preoperative physiologic assessment of accurate patient selection is becoming more important. The variability in an objective measure of cardiorespiratory fitness (peak oxygen consumption (VO2peak )) across performance in operable non-small-cell lung cancer (NSCLC) patients enrolled in the Cancer and Leukemia Group B trial was compared. METHODS: Using a cross-sectional design, 392 NSCLC patients underwent an incremental cardiopulmonary cycling exercise test to symptom limitation with expired gas analysis to determine VO2peak . Performance status (PS) was assessed using the Eastern Cooperative Oncology Group (ECOG) tool. RESULTS: There was a significant decrease in VO2peak across increasing ECOG categories (P < 0.0001). However, there was a large range in VO2peak for any given ECOG category with overlap between categories (ECOG 0: 5.0-31.5 mL/kg/min; ECOG 1: 4.3-24.8 mL/kg/min; ECOG 2: 8.9-21.9 mL/kg/min; ECOG 3; 3.3-11.7 mL/kg/min). CONCLUSIONS: PS scoring systems do not provide a sensitive measure of functional status. Objective measures such as VO2peak may be a useful in the clinical management of oncology patients.
BACKGROUND AND OBJECTIVE: In this era of increasing options for treatment of 'surgical' lung cancerpatients, preoperative physiologic assessment of accurate patient selection is becoming more important. The variability in an objective measure of cardiorespiratory fitness (peak oxygen consumption (VO2peak )) across performance in operable non-small-cell lung cancer (NSCLC) patients enrolled in the Cancer and Leukemia Group B trial was compared. METHODS: Using a cross-sectional design, 392 NSCLCpatients underwent an incremental cardiopulmonary cycling exercise test to symptom limitation with expired gas analysis to determine VO2peak . Performance status (PS) was assessed using the Eastern Cooperative Oncology Group (ECOG) tool. RESULTS: There was a significant decrease in VO2peak across increasing ECOG categories (P < 0.0001). However, there was a large range in VO2peak for any given ECOG category with overlap between categories (ECOG 0: 5.0-31.5 mL/kg/min; ECOG 1: 4.3-24.8 mL/kg/min; ECOG 2: 8.9-21.9 mL/kg/min; ECOG 3; 3.3-11.7 mL/kg/min). CONCLUSIONS: PS scoring systems do not provide a sensitive measure of functional status. Objective measures such as VO2peak may be a useful in the clinical management of oncology patients.
Authors: Lee W Jones; Neil D Eves; John R Mackey; Carolyn J Peddle; Mark Haykowsky; Anil A Joy; Kerry S Courneya; Keith Tankel; Jennifer Spratlin; Tony Reiman Journal: Lung Cancer Date: 2006-11-17 Impact factor: 5.705
Authors: Lee W Jones; Dorothy Watson; James E Herndon; Neil D Eves; Benjamin E Haithcock; Gregory Loewen; Leslie Kohman Journal: Cancer Date: 2010-10-15 Impact factor: 6.860
Authors: Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman Journal: J Neurooncol Date: 2009-02-11 Impact factor: 4.130
Authors: Gary J Balady; Martin G Larson; Ramachandran S Vasan; Eric P Leip; Christopher J O'Donnell; Daniel Levy Journal: Circulation Date: 2004-09-27 Impact factor: 29.690
Authors: Gregory M Loewen; Dorothy Watson; Leslie Kohman; James E Herndon; Hani Shennib; Kemp Kernstine; Jemi Olak; M Jeffery Mador; David Harpole; David Sugarbaker; Mark Green Journal: J Thorac Oncol Date: 2007-07 Impact factor: 15.609